rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    RGEN
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Repligen at Jefferies Global Healthcare Conference: eyeing a 2027 rebound
      14h agoInvesting.comRGENJEF
      Repligen Corporation (RGEN) Presents at Jefferies Global Healthcare Conference 2026 - Slideshow
      14h agoSeeking AlphaRGENJEF
      Repligen (RGEN) Stock Looks Fairly Valued As Cash Flow Growth Matters

      Repligen has had a mixed run, with the share price at US$162.78 after several years of uneven returns. This puts fresh focus on whether the current market value lines up with the cash the business can generate over time. For anyone considering the stock today, the live question is how that cash flow story stacks up against the recent performance profile. Over the past 5 years, Repligen shares have fallen 40.6%, which puts longer term cash flow prospects under the microscope despite shorter...

      Nov 16Yahoo FinanceRGEN
      Repligen: 3 Key Takeaways for Long-Term Investors
      Nov 5Yahoo FinanceRGEN
      Repligen Corporation to Present at Jefferies Global Healthcare Conference
      Nov 4Yahoo FinanceRGEN
      Stifel reiterates Buy on Repligen stock, keeps $207 target
      Nov 2Investing.comRGENSF
      5 must-read analyst questions from Repligen’s Q3 earnings call
      Oct 31Yahoo FinanceRGEN
      Repligen issues $1B in convertible notes, exchanges 2028 debt
      Oct 30Investing.comRGEN
      Repligen to Issue $1 Billion in Convertible Notes Due 2031
      Oct 30Yahoo FinanceRGEN
      Repligen Announces $1 Billion Private Convertible Senior Notes Transaction
      Oct 30Yahoo FinanceRGEN
      Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), Jazz Pharmaceuticals (JAZZ) and Repligen (RGEN)

      Detailed price information for Iqvia Holdings Inc (IQV-N) from The Globe and Mail including charting and trades.

      Oct 29The Globe and MailJAZZRGENIQV
      Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), Repligen (RGEN) and Cooper Co (COO)

      Tipranks Press Release.

      Oct 29The Globe and MailRGENIQV
      Repligen Corporation (RGEN) Surges on Revenue Beat and Raised Full-Year Organic Outlook
      Oct 28Yahoo FinanceRGEN
      Repligen Corporation (RGEN) Benefits From Biotech Momentum and Strong Earnings

      Wasatch Global Investors, an asset management company, released its “Small Cap Growth Strategy” Q3 2026 investor letter. The letter can be downloaded here. The Wasatch Small Cap Growth strategy declined in Q3 2026 but outperformed the Russell 2000 Growth Index, which fell 9.39%. Strong company fundamentals and limited exposure to speculative AI-related stocks supported performance, […]

      Oct 28Yahoo FinanceRGEN
      RBC Raises Price Target on Repligen to $200 From $185, Keeps Outperform Rating
      Oct 28Yahoo FinanceRGEN
      Canaccord reiterates Hold on Repligen stock after Q3 beat
      Oct 28Investing.comRGEN
      Repligen (RGEN) Could Be 12% Undervalued As Record Revenue Lifts Guidance
      Oct 28Yahoo FinanceRGEN
      Record Revenue Outlook Could Be A Game Changer For Repligen (RGEN)
      Oct 27Yahoo FinanceRGEN
      Repligen (RGEN) Takes $41.2 Million Impairment Charge As Quarterly Profit Turns To Loss
      Oct 27Yahoo FinanceRGEN
      Repligen Corp (RGEN) Q3 2026 Earnings Call Highlights: Record Revenue, Raised Guidance, and a ...
      Oct 27Yahoo FinanceRGEN
      Repligen (RGEN) Stock Looks Fairly Valued As Cash Flow Growth Is Priced In
      Oct 27Yahoo FinanceRGEN
      Repligen Corporation Q3 2026 Earnings Call Summary
      Oct 27Yahoo FinanceRGEN
      Repligen (RGEN) Q3 2026 Earnings Call Transcript

      Motley Fool Press Release.

      Oct 27The Globe and MailRGEN
      What Repligen (RGEN) Said on Its Q3 Earnings Call
      Oct 27Yahoo FinanceRGEN
      Repligen Q3 2026 slides: record revenue, raised guidance, margins expand
      Oct 27Investing.comRGEN
      Earnings call transcript: Repligen tops Q3 2026 forecasts but shares slip
      Oct 27Investing.comRGEN
      Repligen Q3 2026 Earnings Call Transcript
      Oct 27BenzingaRGEN
      Repligen Q3 Adjusted Earnings, Revenue Rise; 2026 Adjusted EPS Outlook Narrowed
      Oct 27Yahoo FinanceRGEN
      Repligen (NASDAQ:RGEN) exceeds Q3 2026 expectations, full-year outlook slightly exceeds expectations

      Detailed price information for Repligen Corp (RGEN-Q) from The Globe and Mail including charting and trades.

      Oct 27The Globe and MailRGEN
      Repligen (RGEN) Q3 Earnings and Revenues Surpass Estimates
      Oct 27Yahoo FinanceRGEN
      Repligen earnings beat by $0.07, revenue topped estimates
      Oct 27Investing.comRGEN
      Repligen: Q3 Earnings Snapshot
      Oct 27Yahoo FinanceRGEN
      Repligen Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance
      Oct 27Yahoo FinanceRGEN
      Repligen earnings in focus as bioprocessing growth accelerates
      Oct 26Investing.comRGEN
      Repligen (RGEN) Q3 earnings report preview: what to look for

      Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) will be reporting earnings this Tuesday before market hours. Here’s what to expect.

      Oct 26Yahoo FinanceRGEN
      Repligen (RGEN) Receives a Buy from J.P. Morgan

      Detailed price information for Repligen Corp (RGEN-Q) from The Globe and Mail including charting and trades.

      Oct 18The Globe and MailRGEN
      Azenta, Myriad Genetics, Moderna, Repligen, and PacBio Shares Plummet, What You Need To Know
      Oct 16Yahoo FinanceAZTAMYGNRGEN
      Repligen: A Buy As Its Growth Engine Gears Up (NASDAQ:RGEN)
      Oct 15Seeking AlphaRGEN
      Repligen to Report Third Quarter 2026 Financial Results
      Oct 13Yahoo FinanceRGEN
      BioLife Solutions Completes Repligen Merger and Nasdaq Delisting

      Detailed price information for Biolife Solutions (BLFS-Q) from The Globe and Mail including charting and trades.

      Oct 7The Globe and MailBLFSRGEN
      Repligen Completes BioLife Acquisition to Expand Cell Therapies

      Tipranks Press Release.

      Oct 7The Globe and MailBLFSRGEN
      Repligen CEO Olivier Loeillot sells $1.03m of company stock
      Oct 6Investing.comRGEN
      Repligen Insider Sold Shares Worth $1,036,654, According to a Recent SEC Filing
      Oct 6Yahoo FinanceRGEN
      Repligen Closes BioLife Solutions Acquisition
      Oct 6Yahoo FinanceBLFSRGEN
      Repligen completes acquisition of BioLife Solutions
      Oct 6Investing.comBLFSRGEN
      BioLife Solutions Shareholders Approve Repligen Merger Agreement

      BioLife Solutions (NASDAQ:BLFS) stockholders approved the company’s merger agreement with Repligen Corporation at a special meeting held virtually on Oct. 5, 2026, clearing a key shareholder-vote requirement for the proposed transaction. Roderick de Greef, BioLife’s chief executive officer and chai

      Oct 5Yahoo FinanceBLFSRGEN
      Repligen stock price target reaffirmed at $225 by UBS on growth outlook
      Sep 29Investing.comRGEN
      Repligen CEO Olivier Loeillot sells $976,680 in company stock
      Sep 27Investing.comRGEN
      Repligen CEO Loeillot sells $2.46m in shares
      Sep 26Investing.comRGEN
      Repligen Corporation stock hits 52-week high at 188.95 USD
      Sep 23Investing.comRGEN

      This is the newest page. Registered accounts read further back.